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Mediation analysisChromosome 20q12-q13.1 has been linked to type 2 diabetes (T2D) in multiple populations. We examined
the inﬂuence of genes in this region on T2D and BMI in two European American case–control populations.
SNPs were genotyped in 300 diabetic patients and 310 controls. A subset of 72 SNPs were further genotyped
in 470 cases and 442 controls. All genes examined showed evidence of association with T2D in the initial
sample (additive P-value [Pa]=0.00090–0.045). SNPs near PREX1 were also associated in the second case–
control population (Pa=0.017–0.042). The combined analysis resulted in the same SNPs, among others,
associated with T2D (Pa=0.0013–0.041). Stratiﬁcation analysis by T2D status showed that association with
BMI was observed solely in cases (Pa=0.0018–0.041). Mediation testing revealed that 30–40% of the effects
of these SNPs on T2D were signiﬁcantly mediated by BMI. SNPs near PREX1 may contribute to T2D
susceptibility mediated through effects of adiposity in European Americans.Wake Forest University School
27157, USA. Fax: +1 336 713
en).
Inc.Published by Elsevier Inc.1. Introduction
The 20q12-13.1 region is one of the most consistently replicated
areas of linkage to type 2 diabetesmellitus (T2DM) in family studies in
both Caucasian [1–6] and Asian [7,8] populations. These results
suggest that one or more genes contribute to T2DM susceptibility in
this region. Efforts to identify T2DM genes have hadmixed results. For
example, evaluation of hepatocyte nuclear factor 4-alpha (HNF4A), a
maturity onset diabetes of the young gene, has shown evidence of
association with T2DM [9–11] as well as lack of evidence [12]. The
same is true for other candidates in the area including PTPN1 and
SLC2A10 [13–16]. It is possible that population and genetic heteroge-
neity are an explanation for these seemingly contradictory results.
Additionally, reports have shown signiﬁcant changes in both linkage
signals and p-values when accounting for the effects of BMI [7,8].
Alternatively, these inconsistencies may also suggest that the true
T2DM susceptibility gene(s) has not been identiﬁed or additional loci
remain unidentiﬁed. In a prior SNP survey of a 6 MB region of 20q12-
13.1 in our laboratory three genes: nuclear receptor coactivator 5(NCOA5), cadherin-like 22 (CDH22), and phosphatidylinositol 3, 4, 5-
triphosphate-dependent RAC exchanger 1 (PREX1) [17], with sugges-
tive evidence of association with T2DM were identiﬁed warranting
further investigation. In this study we built on our previous
investigation by targeting these regions for higher density genotyping
compared to our initial screen and evaluating these SNPs in an
additional sample of cases and controls. Additionally, we conducted
more targeted intensive analyses in an attempt to more clearly
understand the effects of genotyped SNPs on T2DM risk andmeasures
of adiposity.
Our objective was to examine the inﬂuence of NCOA5, CDH22, and
PREX1 on T2DMand BMI in two European American (EA) case–control
populations by examining 95 common SNPs in these genes.
2. Results
Ninety ﬁve SNPs were genotyped to investigate evidence of
association with T2DM in the regions containing the NCOA5, CDH22,
and PREX1 genes in European Americans. NCOA5, CDH22, and PREX1
were identiﬁed as possible T2DM susceptibility genes in a SNP survey
covering 6 MB in the 20q12-q13 region [17]. Here these genes were
targeted for higher density SNP genotyping and genotyping in an
additional sample of cases and controls. Fifty SNPs are from
chr20:44,069,142–44,365,336 (UCSC Genome Browser, March 2006
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preproprotein (MMP9), solute carrier family 12 member 5 (SLC12A5),
nuclear receptor coactivator 5 (NCOA5), CD40 antigen isoform 1
precursor (CD40), and cadherin 22 precursor (CDH22). The 45
remaining SNPs were located in chr20:46,441,248–46,757,117
(UCSC; [33]) and encompassed exons 7–40 of the phosphatidylino-
sitol-3,4,5-trisphosphate-dependent RAC exchanger 1 (PREX1) gene
(PREX1 is transcribed in the anti-sense direction) and an approxi-
mately 230 kb area directly 5′ of the PREX1 genic region. All SNPswere
genotyped in the T2DM-ESRD samples while a subset of 72 SNPs were
genotyped in the Diabetes Heart Study (DHS) population. Population
characteristics are shown in Table 1. Brieﬂy, the T2DM-ESRD
population cases and controls were approximately of the same age.
Controls of the T2DM-ESRD population had no BMI data available. In
the DHS population, controls were slightly older than cases but
showed lower levels of adiposity as measured through BMI.
2.1. Association analysis in the T2DM-ESRD population
Initially 95 SNPs were genotyped in a sample of 300 T2DM-ESRD
cases and 310 non-diabetic controls to scan these loci for evidence of
association with T2DM. Results of the single-SNP association analyses
with T2DM for the 72 SNPs that were also genotyped in the DHS
population are shown in Table 2. Results of additional SNPs genotyped
in the T2DM-ESRD population but were not genotyped in the DHS
population are shown in Supplementary Table 1. Genotype frequen-
cies and counts for replicated SNPs are provided in Supplementary
Table 2. In the NCOA5-CDH22 region evidence of association with
T2DM was observed with 10 SNPs (additive P [Pa]=0.00090–0.045).
Two of these SNPs, rs2297200 and rs9074, were located in SLC12A5
with Pa-values of 0.019 and 0.0083, respectively. Three associated
SNPs (rs1537028, rs2903908, and rs1406826) were located in NCOA5
(Pa=0.020, 0.024, and 0.017 respectively) while another, rs2868764
(Pa=0.045), was within 3.2 kb 3′ of the gene. In CDH22, three SNPs
(rs1010310, rs2425786, and rs6074069) showed evidence of associ-
ation with T2DM with Pa-values of 0.00090, 0.011, and 0.022
respectively. rs6032664, located in an intragenic region, was also
nominally associated under the additive model (Pa=0.031) but
deviated from Hardy–Weinberg proportions in the population
(Supplementary Table 2).
In the PREX1 region 11 SNPs showed evidence of association with
T2DM (Pa=0.0012–0.031). Three of these SNPs (rs2664570,
rs2073072, and rs2294910) were located within the PREX1 gene
region (Pa=0.026, 0.031, and 0.013 respectively). The remaining
eight associated SNPs were located 3′ of PREX1 with respect to gene
transcription; PREX1 is coded on the reverse strand to the conven-
tional physical sequence map ‘forward’ direction. A cluster of ﬁve ofTable 1
Population characteristics.
N Mean age±Std.
deviation (years)
Mean BMI±Std.
deviation (kg/m2)
Mean HbA1C
(%)
T2DM-ESRD group
Cases 300† 46.5±12.8 28.5±6.8 8.6
Controls 310 45.8±10.6 – –
Combined 610 46.1±11.5 28.5±6.8 –
DHS group
Cases 470 51.6±9.3 33.0±6.7 7.5
Controls 442⁎ 57.3±13.7 28.1±5.2 –
Combined 912 54.4±11.2 30.6±6.5 –
Entire population
Cases 770† 49.6±10.6 31.2±7.1 7.9
Controls 752⁎ 52.6±12.1 28.1±5.2 –
Combined 1522 51.1±11.6 30.1±6.7 –
⁎ BMI data was available for 407 controls.
† BMI data was available for 291 cases in the ESRD-T2DM groupmaking a total of 761
cases with BMI data in the entire population.these SNPs was positioned in an area of moderate to high linkage
disequilibrium and had Pa-values ranging from 0.010–0.027 (Table 2).
The most signiﬁcant association with T2DM in the PREX1 region was
seen with rs4810813 (P=0.0012) but this marker was inconsistent
with Hardy–Weinberg equilibrium in controls (P=0.026). Two other
SNPs, rs6090875 and rs3924220, were associated with T2DM
(Pa=0.030 and 0.0029 respectively) and both were in high LD with
each other (D′=0.867, r2=0.741).
2.2. Association analysis in the DHS population
A subset of 72 SNPs were also genotyped in 470 samples from
T2DM-affected individuals from the DHS and an independent set of
442 controls. Results of the association analyses for the SNPs
genotyped in the DHS population are shown in Table 2. Genotype
frequencies and counts for each SNP are provided in Supplementary
Table 3. In this cohort none of the SNPs in the NCOA5-CDH22 region or
the PREX1 genic region were signiﬁcantly associated with T2DM.
However, similar to the T2DM-ESRD population, multiple SNPs were
associated with T2DM in the area 3′ of PREX1 (Table 2). Three SNPs
(rs7263053, rs1321006, and rs926692) showed evidence of associa-
tion with T2DM in participants of the DHS (Pa=0.024, 0.020, and
0.041 respectively). Within this region rs999151, rs4809696, and
12481537 also showed nominal evidence with T2DM with Pa-values
of 0.023, 0.017, and 0.042 respectively.
2.3. Association analysis of the combined population
To more thoroughly investigate the effects of the genes we
analyzed the T2DM-ESRD and DHS populations as a single sample
resulting in 770 diabetic cases and 752 healthy controls. Linkage
disequilibrium structure plots of theNCOA5-CDH22 and PREX1 regions
for the SNPs genotyped in this population are shown in Supplemen-
tary Figs. 1 and 2 respectively. Results of the single-SNP association
analyses are shown in Table 2. Genotype frequencies and counts for
each SNP are provided in Supplementary Table 4. In theNCOA5-CDH22
region a single SNP (CDH22 SNP rs1010310) was nominally associated
with T2DM (Pa=0.019). All other SNPs in this region failed to show
evidence of association (Table 2). In the PREX1 region nine SNPs
showed evidence of association with T2DM (Pa-values ranging from
0.0013 to 0.041). None of these SNPs were located within the PREX1
gene sequence. Consistent with analyses of the individual popula-
tions, the associated SNPs in the combined sample were clustered in
the 3′ region of PREX1 transcription. Six of these SNPs resided in a
region of high LD and generally showed stronger evidence of
association compared to the evaluation of the T2DM-ESRD or DHS
populations separately (Supplementary Fig. 1 and Table 2). Two other
SNPs (rs6019212 and rs12481537) in high LD with the six SNP block
(D′N0.70 for all inter-SNP combinations, data not shown) were
associated with T2DM as well (Pa=0.013 and 0.034 respectively).
rs4810813 also showed modest evidence of association with T2DM
(Pa=0.013) and was not in high LD with any other associated SNP.
In order to determine whether combinations of alleles from
associated SNPs 3′ of PREX1 led to enhanced T2DM risk we performed
extensive haplotypic association analyses in the region. Based on the
single-SNP association results and the LD structure in the combined
population multiple haplotypes were evaluated. From these analyses
the most signiﬁcantly associated haplotypes consisted of alleles from
ﬁve contiguous SNPs: rs7263053, rs1321006, rs4809696, rs926693,
and rs926692 (Global P=3.26×10−6). Upon further investigationwe
observed several rare haplotypes in this region with frequencies less
than 0.02. To evaluate the effect these uncommon haplotypes
contributed to T2DM risk we repeated the analysis excluding
haplotypes with frequencies less than 0.02. When evaluating only
common haplotypes we still observed evidence of association with
T2DM (Global P=0.0044) (Table 3). The most common haplotype in
Table 2
Single-SNP additive test of association with T2DM in T2DM-ESRD, DHS, and combined populations.
ESRD-DHS population T2DM-ESRD population DHS population ESRD-DHS population
Gene SNP Position (kb) Major/
minor
alleles
Minor allele
frequency
cases
Minor allele
frequency
controls
Pa-value OR (95% CI) Pa-value OR (95% CI) Pa-value OR (95% CI)
MMP9 rs3918241 44,069.142 T/A 0.148 0.137 0.2254 1.22 (0.88–1.68) 0.9176 1.01 (0.78–1.32) 0.3781 1.10 (0.89–1.34)
rs20544 44,078.417 T/C 0.417 0.410 0.3206 1.12 (0.89–1.41) 0.7632 0.97 (0.80–1.18) 0.6996 1.03 (0.89–1.19)
rs6130998 44,086.526 C/T 0.204 0.189 0.9004 1.02 (0.76–1.36) 0.2185 1.16 (0.92–1.46) 0.2928 1.10 (0.92–1.32)
SLC12A5 rs3848726 44,100.003 G/T 0.374 0.392 0.2478 0.87 (0.68–1.10) 0.7187 0.96 (0.80–1.17) 0.3103 0.93 (0.80–1.07)
rs2297198 44,107.690 C/T 0.207 0.200 0.4246 1.12 (0.84–1.50) 0.9789 1.00 (0.79–1.27) 0.5887 1.05 (0.88–1.26)
rs2297200 44,117.933 T/A 0.328 0.326 0.0193 1.33 (1.04–1.70) 0.0830 0.84 (0.69–1.02) 0.9064 1.01 (0.87–1.17)
rs2297201 44,118.385 C/T 0.061 0.070 0.7937 1.06 (0.70–1.61) 0.1208 0.75 (0.51–1.09) 0.3262 0.87 (0.65–1.15)
rs9074 44,122.072 G/A 0.249 0.271 0.0083 0.70 (0.54–0.91) 0.6251 1.06 (0.85–1.31) 0.1656 0.89 (0.75–1.05)
NCOA5 rs1537028 44,124.757 T/G 0.331 0.328 0.0196 1.33 (1.04–1.71) 0.1181 0.85 (0.70–1.04) 0.8488 1.02 (0.87–1.18)
rs2903908 44,127.354 T/C 0.269 0.264 0.0237 1.35 (1.04–1.75) 0.1429 0.86 (0.69–1.06) 0.7582 1.03 (0.87–1.21)
rs3092502 44,130.838 G/T 0.449 0.456 0.0699 0.81 (0.64–1.02) 0.3169 1.10 (0.91–1.33) 0.7052 0.97 (0.84–1.13)
rs1406826 44,140.771 A/G 0.449 0.463 0.0168 0.75 (0.59–0.95) 0.3368 1.10 (0.91–1.33) 0.4634 0.95 (0.82–1.10)
rs1950174 44,147.811 C/A 0.208 0.210 0.2038 0.83 (0.62–1.11) 0.4436 1.09 (0.87–1.36) 0.9015 0.99 (0.83–1.18)
rs6065921 44,147.917 A/G 0.191 0.187 0.7786 1.04 (0.78–1.40) 0.8922 1.02 (0.81–1.28) 0.7594 1.03 (0.86–1.24)
rs2868764 44,155.418 T/G 0.448 0.461 0.0445 0.79 (0.63–0.99) 0.4849 1.07 (0.89–1.30) 0.4446 0.95 (0.82–1.09)
rs6032664 44,172.826 T/A 0.235 0.250 0.0306 0.75 (0.58–0.97) 0.4497 1.09 (0.87–1.36) 0.3681 0.93 (0.79–1.09)
CD40 rs3746821 44,188.518 G/T 0.111 0.108 0.1237 0.75 (0.53–1.08) 0.0987 1.30 (0.95–1.78) 0.8127 1.03 (0.81–1.30)
rs1535043 44,201.131 T/A 0.440 0.447 0.7283 1.04 (0.83–1.30) 0.4563 0.93 (0.78–1.12) 0.7281 0.98 (0.85–1.13)
rs2064405 44,210.912 G/T 0.105 0.100 0.3136 0.83 (0.58–1.19) 0.1478 1.27 (0.92–1.75) 0.6788 1.05 (0.83–1.34)
rs2425754 44,222.040 G/A 0.139 0.143 0.6208 0.92 (0.66–1.28) 0.9742 1.00 (0.76–1.31) 0.7052 0.96 (0.78–1.19)
CDH22 rs6131030 44,241.394 G/A 0.390 0.377 0.4616 1.09 (0.86–1.38) 0.7946 1.03 (0.85–1.24) 0.5003 1.05 (0.91–1.22)
rs6074061 44,246.711 C/G 0.272 0.279 0.8967 0.98 (0.77–1.26) 0.6310 0.95 (0.77–1.17) 0.6340 0.96 (0.82–1.13)
rs1321001 44,250.143 T/G 0.173 0.152 0.0510 1.33 (0.99–1.77) 0.6875 1.05 (0.82–1.36) 0.1253 1.16 (0.96–1.41)
rs4383400 44,253.272 T/C 0.066 0.052 0.0571 1.49 (0.98–2.26) 0.7317 1.07 (0.71–1.62) 0.1262 1.26 (0.94–1.69)
rs2868767 44,258.031 A/G 0.180 0.183 0.5940 1.08 (0.81–1.45) 0.4829 0.91 (0.71–1.17) 0.8279 0.98 (0.81–1.18)
rs1010310 44,268.451 C/A 0.292 0.331 0.0009 0.67 (0.52–0.86) 0.7090 0.96 (0.78–1.18) 0.0191 0.83 (0.71–0.97)
rs2425785 44,272.729 G/C 0.351 0.328 0.0646 1.26 (0.99–1.61) 0.8791 1.02 (0.84–1.23) 0.1872 1.11 (0.95–1.29)
rs2425786 44,277.882 T/C 0.330 0.313 0.0108 1.38 (1.08–1.77) 0.3977 0.91 (0.74–1.12) 0.3216 1.08 (0.92–1.27)
rs761048 44,284.465 G/C 0.074 0.082 0.3866 0.84 (0.57–1.25) 0.7534 0.95 (0.66–1.35) 0.3871 0.89 (0.68–1.16)
rs6074069 44,288.133 G/A 0.219 0.206 0.0221 1.38 (1.04–1.84) 0.5068 0.93 (0.73–1.17) 0.3780 1.08 (0.91–1.30)
rs2050113 44,293.878 A/C 0.075 0.081 0.7841 0.95 (0.64–1.42) 0.5401 0.90 (0.63–1.27) 0.5065 0.91 (0.70–1.19)
rs966567 44,300.632 G/C 0.247 0.231 0.0532 1.30 (0.99–1.70) 0.9129 0.99 (0.79–1.23) 0.2859 1.10 (0.93–1.30)
rs3904166 44,306.828 C/A 0.243 0.227 0.0705 1.29 (0.98–1.69) 0.9227 0.99 (0.80–1.23) 0.2982 1.09 (0.92–1.30)
rs3848729 44,308.103 G/T 0.361 0.356 0.8748 0.98 (0.77–1.25) 0.6653 1.04 (0.86–1.26) 0.7897 1.02 (0.88–1.18)
rs2425807 44,314.952 A/G 0.428 0.439 0.9567 1.01 (0.79–1.27) 0.3878 0.92 (0.77–1.11) 0.5451 0.96 (0.83–1.11)
rs2425809 44,321.008 C/T 0.447 0.454 0.8441 0.98 (0.77–1.23) 0.6887 0.96 (0.80–1.16) 0.6829 0.97 (0.84–1.12)
rs2425817 44,328.693 G/A 0.445 0.458 0.4385 0.92 (0.73–1.15) 0.7526 0.97 (0.80–1.17) 0.4904 0.95 (0.82–1.10)
rs2425855 44,344.506 T/A 0.464 0.458 0.4536 1.10 (0.87–1.39) 0.8583 0.98 (0.82–1.18) 0.7499 1.02 (0.89–1.18)
rs6032754 44,352.166 T/C 0.263 0.260 0.3428 1.13 (0.88–1.46) 0.5904 0.94 (0.76–1.17) 0.8339 1.02 (0.86–1.20)
rs6017767 44,365.336 C/G 0.475 0.494 0.1061 0.83 (0.66–1.04) 0.9768 1.00 (0.82–1.20) 0.2887 0.92 (0.80–1.07)
rs6095091 46,441.248 C/T 0.261 0.260 0.6237 1.07 (0.82–1.39) 0.7561 0.97 (0.79–1.19) 0.9504 1.01 (0.85–1.18)
rs6066724 46,451.845 G/A 0.289 0.286 0.8435 0.97 (0.76–1.25) 0.6920 1.04 (0.85–1.28) 0.8523 1.01 (0.87–1.19)
rs2008645 46,458.897 G/A 0.418 0.424 0.6372 0.95 (0.75–1.19) 0.9372 0.99 (0.83–1.19) 0.7427 0.98 (0.85–1.13)
rs4809688 46,461.222 A/G 0.433 0.447 0.3206 0.89 (0.71–1.12) 0.8746 0.98 (0.82–1.19) 0.4587 0.95 (0.82–1.09)
Replicated region
3′ of PREX1
rs999151 46,488.676 C/T 0.302 0.269 0.5953 1.07 (0.83–1.39) 0.0297 1.26 (1.02–1.56) 0.0411 1.18 (1.00–1.40)
rs7263053 46,496.933 C/T 0.288 0.237 0.0263 1.36 (1.04–1.78) 0.0244 1.28 (1.03–1.58) 0.0013 1.31 (1.11–1.55)
rs1321006 46,499.668 G/A 0.374 0.318 0.0194 1.34 (1.05–1.72) 0.0199 1.26 (1.03–1.54) 0.0013 1.29 (1.11–1.51)
rs4809696 46,507.214 T/C 0.369 0.318 0.0534 1.28 (1.00–1.63) 0.0174 1.27 (1.04–1.55) 0.0030 1.27 (1.09–1.48)
rs926693 46,512.364 A/G 0.491 0.434 0.0103 1.35 (1.08–1.70) 0.0569 1.20 (0.99–1.44) 0.0022 1.25 (1.09–1.45)
rs926692 46,515.682 A/C 0.494 0.435 0.0103 1.36 (1.08–1.72) 0.0413 1.22 (1.01–1.46) 0.0016 1.27 (1.09–1.46)
rs12624650 46,526.719 G/A 0.203 0.191 0.3767 1.13 (0.86–1.50) 0.7423 1.04 (0.83–1.30) 0.4024 1.08 (0.90–1.28)
rs6019212 46,527.953 G/T 0.479 0.433 0.0268 1.29 (1.03–1.63) 0.1467 1.15 (0.95–1.38) 0.0131 1.20 (1.04–1.38)
rs6019216 46,530.327 G/A 0.285 0.252 0.0921 1.24 (0.97–1.58) 0.2481 1.13 (0.92–1.38) 0.0532 1.17 (1.00–1.37)
rs6122689 46,533.130 C/T 0.184 0.159 0.1303 1.26 (0.94–1.71) 0.2602 1.16 (0.90–1.49) 0.0656 1.20 (0.99–1.45)
rs12481537 46,572.852 A/G 0.492 0.453 0.3588 1.11 (0.89–1.39) 0.0418 1.21 (1.01–1.47) 0.0343 1.17 (1.01–1.35)
rs2904081 46,593.440 C/G 0.310 0.283 0.2670 1.16 (0.89–1.52) 0.2387 1.13 (0.92–1.38) 0.0965 1.14 (0.97–1.34)
rs4810813 46,601.875 T/C 0.325 0.283 0.0012 1.54 (1.17–2.02) 0.4499 1.08 (0.88–1.32) 0.0134 1.22 (1.04–1.44)
rs6019300 46,634.916 A/G 0.470 0.449 0.7097 0.96 (0.76–1.20) 0.0531 1.22 (1.00–1.49) 0.2437 1.09 (0.94–1.27)
rs6090875 46,641.633 T/C 0.242 0.227 0.0295 1.34 (1.02–1.76) 0.6288 0.94 (0.75–1.18) 0.3237 1.09 (0.92–1.30)
rs3924220 46,642.853 T/C 0.244 0.224 0.0029 1.51 (1.15–1.98) 0.4404 0.92 (0.73–1.14) 0.1966 1.12 (0.94–1.33)
rs4810837 46,662.565 T/G 0.409 0.400 0.1565 1.19 (0.94–1.50) 0.5477 0.95 (0.79–1.14) 0.6365 1.04 (0.90–1.20)
rs6012501 46,672.841 G/C 0.434 0.420 0.0868 1.23 (0.97–1.56) 0.7426 0.97 (0.81–1.16) 0.4274 1.06 (0.92–1.23)
PREX1 rs2664570 46,674.765 C/T 0.209 0.196 0.0256 1.39 (1.04–1.86) 0.5165 0.93 (0.73–1.17) 0.3775 1.09 (0.91–1.30)
rs3935549 46,686.895 C/T 0.488 0.499 0.5336 0.93 (0.75–1.16) 0.6918 0.96 (0.80–1.16) 0.4874 0.95 (0.83–1.09)
rs2073072 46,703.010 C/G 0.202 0.194 0.0311 1.39 (1.03–1.88) 0.3391 0.89 (0.71–1.13) 0.5696 1.06 (0.88–1.27)
rs2294910 46,709.789 A/G 0.204 0.190 0.0126 1.47 (1.09–1.98) 0.4515 0.92 (0.73–1.16) 0.3406 1.09 (0.91–1.32)
rs6095228 46,713.283 G/A 0.077 0.087 0.4748 0.85 (0.55–1.34) 0.5192 0.91 (0.69–1.21) 0.3743 0.90 (0.71–1.14)
rs6012506 46,719.044 A/G 0.477 0.465 0.2798 1.14 (0.90–1.43) 0.9665 1.00 (0.83–1.20) 0.5190 1.05 (0.91–1.21)
rs6095239 46,730.946 G/A 0.332 0.325 0.4730 1.09 (0.86–1.39) 0.9791 1.00 (0.81–1.22) 0.6752 1.03 (0.88–1.21)
rs3746819 46,741.342 A/G 0.085 0.088 0.3016 0.80 (0.52–1.24) 0.7886 1.04 (0.76–1.43) 0.7091 0.95 (0.74–1.23)
rs4809718 46,744.395 T/A 0.213 0.219 0.1877 0.84 (0.64–1.09) 0.5525 1.07 (0.85–1.35) 0.6849 0.96 (0.81–1.15)
rs736659 46,757.117 G/A 0.218 0.220 0.3608 0.88 (0.68–1.15) 0.5412 1.07 (0.86–1.35) 0.8823 0.99 (0.83–1.17)
Bold: P-valuesb0.05 and corresponding OR.
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Table 3
Haplotype analysis of ﬁve-SNP haplotypes 3′ of PREX1 in the combined population.
Haplotype (rs7263053, rs1321006,
rs4809696, rs926693, and rs926692)
Case frequency
(%)
Control frequency
(%)
Empirical Hap-speciﬁc
P-value
OR (95% CI) Global simulated
P-value
CGTAT 0.506 0.561 0.003 0.87 (0.75–0.99) 0.004
TACGG 0.290 0.224 5.93×10−4 1.41 (1.19–1.67)
CGTGG 0.125 0.130 0.660 0.99 (0.79–1.23)
CACGG 0.081 0.077 0.685 1.09 (0.84–1.41)
Haplotypes with frequenciesb0.02 were excluded from this analysis. Bold: P-valuesb0.05.
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was associated with protection from T2DM with a haplotype-speciﬁc
P-value of 0.0032 (OR=0.87) while the 2ndmost common haplotype
(frequency=0.290 and 0.224 respectively) was associated with
increased risk for T2DM with a haplotype-speciﬁc P-value of
5.93×10−4 and OR of 1.41 (Table 3).
To explore the possible effect of adiposity on T2DM risk in the
combined population an association analysiswas repeated adjusting for
BMI using SNPADDMIX (Table 4). BMI data was available for 761 cases
and 407 controls (Table 1). Evidence of association with T2DM in the
region 3′ of PREX1was similar in this subset of individuals prior to BMI
adjustment (data not shown). However, after BMI adjustment evidence
of associationwith T2DMwas substantially reduced. SNPs rs926693 and
rs926692 remained marginally associated with T2DM after BMI
adjustment (Pa=0.044 and 0.030 respectively) and six other SNPs in
the region were trending towards signiﬁcance (Pa-values ranging from
0.055 to 0.092).
Based on the BMI-adjustment results of the T2DM association
analysis, SNPs were tested for association with BMI itself (Table 5). In
the region 3′ of PREX1 10 SNPs were signiﬁcantly associated with BMI
in the combined population (Pa-values ranging from 0.0015 to 0.029):
evidence of association comparable to that observed with T2DM
(Table 5). The effect size of these SNPs ranged from 0.010 to 0.015 U of
log-transformed BMI for each copy of BMI-increasing allele. For the
most associated SNP in the region, rs999151, individuals with CT and
TT genotypes have a 1.16 kg/m2 and 1.87 kg/m2 increase in BMIwhen
compared to CC carriers respectively.
In an effort to clarify the relationship between the SNPs 3′ of PREX1,
BMI, and T2DM, we further evaluated association with BMI in the case
and control populations separately. In the control population, which
consisted of 407 individuals, no SNP in the region 3′ of PREX1 showed
evidence of association with BMI (Table 5). However, in the case
population, which consisted of 761 individuals (Table 5), multiple SNPs
in the region3′of PREX1wereassociatedwithBMI including12 adjacent
genotyped SNPs showing evidence of association with Pa-value ranging
from 0.0018 to 0.041.
The observation that SNPs in the region 3′ of PREX1 were
associated with BMI solely in the case stratum suggested that BMI
may mediate the effect of these SNPs on T2DM risk. Therefore, a
formal mediation analysis was performed assuming the independent
variable (SNP genotype) signiﬁcantly affected the dependent variable
(T2DM status). Only SNPs associated with T2DM in the subjects with
BMI data (761 cases and 407 controls) were tested for mediation by
BMI. Seven SNPs, all in the region 3′ of PREX1, were associated with
T2DM in this population (Table 6) and the mediation analysis
revealed that 30–40% of the effects of six of these SNPs on T2DM
were signiﬁcantly mediated by BMI according to both the Sobel and
Goodman tests of mediation (Table 6).
3. Discussion
Recently, several genome-wide association (GWA) and candidate
gene studies have reported evidence for multiple type 2 diabetes
mellitus susceptibility genes throughout the genome [34–38]. Eventhough these publications have provided a wealth of information for
diabetes investigators, it is now clear that these genome-wide
approaches account for 20% or less of the genetic risk for T2DM. This
suggests that other more targeted approaches which encompass in
depth analysis of data will be productive in identifying new loci.
Historically, the 20q12-13.1 region of chromosome20 is one of themost
consistently replicated areas of linkage to T2DM in family studies [1–8].
Conﬂicting results from numerous candidate gene studies in the region
leads to the question of whether or not the T2DM risk loci have indeed
been identiﬁed. Based on prior data from a dense SNP map of
chromosome 20q13.1 performed at our center [17] we have performed
a detailed evaluation of the candidate genes NCOA5, CDH22, and PREX1.
In our T2DM-ESRD population consisting of 300 diabetic cases with
ESRD and 310 healthy controls we observed evidence of association
with T2DM in the NCOA5, CDH22, and PREX1 gene regions. Seven SNPs
genotyped between intron 21 of SLC12A5 throughout all of the NCOA5
sequence to approximately 30 kb 3′ of NCOA5 were associated with
T2DM. SLC12A5 is a potassium-chloride cotransporter that maintains
intracellular chloride concentrations but is not expressed in tissues that
seem directly involved in either T2DM or nephropathy [39]. NCOA5
encodes a coregulator for the alpha and beta estrogen receptors [40].
Alpha estrogen receptor knockout mice are insulin resistant, obese, and
have impaired glucose tolerance [41]. Preliminary functional studies in
our laboratory have shown moderate levels of NCOA5 in L6 and C2C12
skeletal muscle cell lines (data not shown). Three SNPs located from
intron 3 to intron 6 of CDH22 were associated with T2DM. CDH22
encodes a calcium-dependent cell adhesion protein that is involved in
morphogenesis and tissue formation and is expressed in diabetes-
related tissues such as pancreatic beta cells and liver [42]. Eleven SNPs
were associated with T2DM in the PREX1 region. Three of these SNPs
were located from intron 16 to the 3′ UTR of PREX1 while most of the
evidence of association with T2DM was observed 3′ of the gene
sequence. PREX1 encodes a guanine exchange factor for different RAC
proteins in multiple cell types and is activated by the lipid second
messenger phosphatidylinositol 3, 4, 5-triphosphate, generated by
phosphoinositide 3-kinase (PI3K) and theβγ subunits of heterotrimeric
G-proteins [43,44]. There is evidence that the PREX1 protein directly
affects RAC1 and RAC2 activity [45]. RAC1 is a member of the Rho
subfamily of small GTP-binding proteins and its activity has been
implicated in cytoskeletal (actin) reorganization, solute carrier family 2
(facilitated glucose transporter), member 4 (SLC2A4) translocation, and
insulin secretion [46,47]. Therefore, it could be hypothesized that
changes in the PREX1 sequence, its expression, or its protein could
inﬂuence the diabetes-related traits mediated by RAC1.
Despite the evidence of association with T2DM in our T2DM-ESRD
population we failed to replicate observed associations nearNCOA5 and
CDH22 in the DHS sample population. This may reﬂect a lack of power
given the small sample sizes of the T2DM-ESRD or DHS populations and
themoderate effect sizes observed in the initial T2DM-ESRD population
data. Recently however, association of CDH22with T2DMwas observed
in a genome-wide association study of a Scandinavian population [34].
In addition, genotyping of NCOA5 SNPs in samples from the Insulin
Resistance Atherosclerosis Study has provided suggestive evidence of
association with SNPs located in NCOA5 with various quantitative
Table 4
Single-SNP tests of association with T2DM adjusted for BMI (ESRD-DHS population).
Gene SNP Position (kb) Major/minor
alleles
Minor allele
frequency cases
Minor allele
frequency controls
Pa-value OR (95% CI)
MMP9 rs3918241 44,069.142 T/A 0.149 0.146 0.5409 1.08 (0.84–1.39)
rs20544 44,078.417 T/C 0.417 0.425 0.8752 1.01 (0.85–1.22)
rs6130998 44,086.526 C/T 0.205 0.196 0.5769 1.07 (0.85–1.33)
SLC12A5 rs3848726 44,100.003 G/T 0.374 0.390 0.3707 0.92 (0.77–1.10)
rs2297198 44,107.690 C/T 0.209 0.207 0.8507 1.02 (0.82–1.28)
rs2297200 44,117.933 T/A 0.330 0.342 0.6478 0.96 (0.80–1.15)
rs2297201 44,118.385 C/T 0.061 0.066 0.5736 0.90 (0.63–1.29)
rs9074 44,122.072 G/A 0.248 0.246 0.8036 1.03 (0.84–1.26)
NCOA5 rs1537028 44,124.757 T/G 0.333 0.338 0.8882 0.99 (0.82–1.19)
rs2903908 44,127.354 T/C 0.270 0.286 0.4415 0.93 (0.76–1.13)
rs3092502 44,130.838 G/T 0.448 0.438 0.4665 1.07 (0.89–1.28)
rs1406826 44,140.771 A/G 0.449 0.442 0.5833 1.05 (0.88–1.26)
rs1950174 44,147.811 C/A 0.208 0.217 0.3365 0.90 (0.73–1.12)
rs6065921 44,147.917 A/G 0.190 0.195 0.9420 0.99 (0.79–1.24)
rs2868764 44,155.418 T/G 0.447 0.443 0.6388 1.04 (0.87–1.25)
rs6032664 44,172.826 T/A 0.235 0.223 0.4161 1.09 (0.89–1.34)
CD40 rs3746821 44,188.518 G/T 0.110 0.091 0.0992 1.29 (0.95–1.75)
rs1535043 44,201.131 T/A 0.440 0.463 0.3283 0.92 (0.77–1.09)
rs2064405 44,210.912 G/T 0.104 0.087 0.1208 1.28 (0.94–1.74)
rs2425754 44,222.040 G/A 0.137 0.142 0.6543 0.94 (0.73–1.22)
CDH22 rs6131030 44,241.394 G/A 0.390 0.376 0.4270 1.08 (0.90–1.29)
rs6074061 44,246.711 C/G 0.272 0.279 0.9198 0.99 (0.81–1.20)
rs1321001 44,250.143 T/G 0.174 0.147 0.1149 1.21 (0.95–1.55)
rs4383400 44,253.272 T/C 0.067 0.048 0.1573 1.31 (0.90–1.91)
rs2868767 44,258.031 A/G 0.180 0.181 0.9527 0.99 (0.79–1.25)
rs1010310 44,268.451 C/A 0.294 0.318 0.1971 0.88 (0.72–1.07)
rs2425785 44,272.729 G/C 0.351 0.344 0.5299 1.06 (0.88–1.27)
rs2425786 44,277.882 T/C 0.330 0.312 0.4619 1.07 (0.89–1.30)
rs761048 44,284.465 G/C 0.074 0.069 0.9006 0.98 (0.69–1.38)
rs6074069 44,288.133 G/A 0.219 0.207 0.4121 1.09 (0.88–1.36)
rs2050113 44,293.878 A/C 0.075 0.075 0.6678 0.93 (0.66–1.30)
rs966567 44,300.632 G/C 0.248 0.231 0.3345 1.11 (0.90–1.36)
rs3904166 44,306.828 C/A 0.244 0.226 0.3125 1.11 (0.91–1.36)
rs3848729 44,308.103 G/T 0.362 0.358 0.7501 0.97 (0.81–1.16)
rs2425807 44,314.952 A/G 0.429 0.456 0.1471 0.88 (0.73–1.05)
rs2425809 44,321.008 C/T 0.448 0.467 0.2672 0.90 (0.75–1.08)
rs2425817 44,328.693 G/A 0.446 0.466 0.2638 0.90 (0.76–1.08)
rs2425855 44,344.506 T/A 0.465 0.473 0.6489 0.96 (0.81–1.14)
rs6032754 44,352.166 T/C 0.264 0.265 0.8399 1.02 (0.84–1.24)
rs6017767 44,365.336 C/G 0.473 0.491 0.2973 0.91 (0.76–1.09)
rs6095091 46,441.248 C/T 0.261 0.264 0.4615 0.93 (0.76–1.13)
rs6066724 46,451.845 G/A 0.289 0.290 0.4338 0.92 (0.76–1.13)
rs2008645 46,458.897 G/A 0.418 0.432 0.2778 0.91 (0.76–1.08)
rs4809688 46,461.222 A/G 0.432 0.449 0.2889 0.91 (0.76–1.08)
Replicated region 3′ of PREX1 rs999151 46,488.676 C/T 0.300 0.273 0.5161 1.07 (0.87–1.31)
rs7263053 46,496.933 C/T 0.285 0.251 0.2228 1.13 (0.93–1.39)
rs1321006 46,499.668 G/A 0.372 0.323 0.0804 1.18 (0.98–1.43)
rs4809696 46,507.214 T/C 0.368 0.321 0.0921 1.18 (0.97–1.42)
rs926693 46,512.364 A/G 0.491 0.434 0.0442 1.20 (1.00–1.43)
rs926692 46,515.682 A/C 0.493 0.433 0.0296 1.22 (1.02–1.46)
rs12624650 46,526.719 G/A 0.204 0.197 0.9284 1.01 (0.82–1.25)
rs6019212 46,527.953 G/T 0.479 0.428 0.0812 1.17 (0.98–1.39)
rs6019216 46,530.327 G/A 0.286 0.244 0.0668 1.20 (0.99–1.46)
rs6122689 46,533.130 C/T 0.183 0.162 0.3881 1.11 (0.88–1.41)
rs12481537 46,572.852 A/G 0.492 0.439 0.0551 1.19 (1.00–1.42)
rs2904081 46,593.440 C/G 0.310 0.291 0.3480 1.10 (0.90–1.33)
rs4810813 46,601.875 T/C 0.325 0.308 0.4122 1.08 (0.90–1.31)
rs6019300 46,634.916 A/G 0.469 0.430 0.0682 1.19 (0.99–1.44)
rs6090875 46,641.633 T/C 0.242 0.240 0.9232 1.01 (0.82–1.25)
rs3924220 46,642.853 T/C 0.243 0.244 0.9131 0.99 (0.80–1.22)
rs4810837 46,662.565 T/G 0.407 0.437 0.1841 0.89 (0.74–1.06)
rs6012501 46,672.841 G/C 0.433 0.451 0.4630 0.94 (0.79–1.12)
PREX1 rs2664570 46,674.765 C/T 0.208 0.212 0.9822 1.00 (0.81–1.25)
rs3935549 46,686.895 C/T 0.489 0.489 0.9594 1.00 (0.84–1.19)
rs2073072 46,703.010 C/G 0.202 0.210 0.6025 0.94 (0.76–1.18)
rs2294910 46,709.789 A/G 0.203 0.208 0.7711 0.97 (0.78–1.21)
rs6095228 6713.283 G/A 0.078 0.104 0.0803 0.79 (0.60–1.03)
rs6012506 46,719.044 A/G 0.475 0.480 0.8122 0.98 (0.82–1.17)
rs6095239 46,730.946 G/A 0.333 0.329 0.8153 1.02 (0.84–1.24)
rs3746819 46,741.342 A/G 0.085 0.099 0.3775 0.87 (0.65–1.18)
rs4809718 46,744.395 T/A 0.211 0.211 0.9583 0.99 (0.80–1.23)
rs736659 46,757.117 G/A 0.216 0.211 0.7848 1.03 (0.83–1.28)
Bold: P-valuesb0.05 and corresponding OR.
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Table 5
Single-SNP tests of association with BMI (ESRD-DHS population).
Combined population Cases only Controls only
Gene SNP Position (kb) Major/minor
alleles
Minor allele
frequency
Additive
P-value
β±SE Additive
P-value
β±SE Additive
P-value
β±SE
MMP9 rs3918241 44,069.142 T/A 0.148 0.0628 −0.010±0.006 0.0763 −0.012±0.007 0.4191 −0.007±0.008
rs20544 44,078.417 T/C 0.420 0.0105 −0.009±0.004 0.0121 −0.012±0.005 0.4975 −0.003±0.006
rs6130998 44,086.526 C/T 0.202 0.9588 0.000±0.005 0.9190 −0.001±0.006 0.8569 0.000±0.007
SLC12A5 rs3848726 44,100.003 G/T 0.379 0.5163 0.002±0.004 0.5365 0.003±0.005 0.5379 0.003±0.006
rs2297198 44,107.690 C/T 0.208 0.5791 −0.002±0.005 0.4020 −0.005±0.006 0.7411 0.004±0.007
rs2297200 44,117.933 T/A 0.334 0.6902 −0.002±0.004 0.9803 −0.002±0.005 0.5892 −0.003±0.006
rs2297201 44,118.385 C/T 0.062 0.5738 0.003±0.008 0.2019 0.011±0.010 0.3183 −0.011±0.012
rs9074 44,122.072 G/A 0.247 0.4453 −0.002±0.005 0.4894 −0.003±0.006 0.6769 −0.002±0.007
NCOA5 rs1537028 44,124.757 T/G 0.335 0.7710 −0.002±0.004 0.9846 −0.002±0.005 0.6425 −0.002±0.006
rs2903908 44,127.354 T/C 0.276 0.7295 −0.002±0.004 0.7881 −0.003±0.006 0.8927 0.002±0.006
rs3092502 44,130.838 G/T 0.445 0.2287 −0.004±0.004 0.1583 −0.006±0.005 0.8456 −0.002±0.006
rs1406826 44,140.771 A/G 0.447 0.2736 −0.004±0.004 0.1743 −0.006±0.005 0.9784 0.000±0.006
rs1950174 44,147.811 C/A 0.211 0.1169 0.008±0.005 0.1293 0.010±0.006 0.4001 0.006±0.007
rs6065921 44,147.917 A/G 0.192 0.5812 −0.004±0.005 0.5225 −0.004±0.006 0.9178 −0.001±0.007
rs2868764 44,155.418 T/G 0.445 0.2133 −0.004±0.004 0.1621 −0.006±0.005 0.8534 −0.001±0.006
rs6032664 44,172.826 T/A 0.230 0.3123 −0.003±0.005 0.1764 −0.006±0.006 0.9680 0.001±0.007
CD40 rs3746821 44,188.518 G/T 0.104 0.3864 −0.005±0.006 0.1216 −0.012±0.008 0.6696 0.004±0.010
rs1535043 44,201.131 T/A 0.448 0.7317 −0.001±0.004 0.6996 −0.002±0.005 0.6441 0.003±0.006
rs2064405 44,210.912 G/T 0.098 0.4413 −0.005±0.007 0.1759 −0.012±0.008 0.7779 0.003±0.010
rs2425754 44,222.040 G/A 0.139 0.8272 0.001±0.006 0.5980 0.004±0.007 0.7508 −0.001±0.008
CDH22 rs6131030 44,241.394 G/A 0.385 0.7158 −0.002±0.004 0.3584 −0.004±0.005 0.5555 0.002±0.006
rs6074061 44,246.711 C/G 0.275 0.2439 −0.005±0.004 0.1045 −0.008±0.006 0.5423 0.002±0.006
rs1321001 44,250.143 T/G 0.164 0.6618 0.002±0.005 0.5954 0.003±0.006 0.3787 −0.005±0.008
rs4383400 44,253.272 T/C 0.060 0.1432 0.012±0.008 0.4964 0.006±0.009 0.2441 0.017±0.013
rs2868767 44,258.031 A/G 0.181 0.8945 0.000±0.005 0.6289 0.002±0.006 0.5354 −0.004±0.008
rs1010310 44,268.451 C/A 0.302 0.6530 0.001±0.004 0.3653 0.004±0.006 0.8965 0.000±0.006
rs2425785 44,272.729 G/C 0.349 0.1778 −0.005±0.004 0.0506 −0.010±0.005 0.5873 0.003±0.006
rs2425786 44,277.882 T/C 0.324 0.4132 0.004±0.004 0.7151 −0.002±0.005 0.0376 0.013±0.006
rs761048 44,284.465 G/C 0.072 0.0101 −0.014±0.003 0.0588 −0.017±0.009 0.0681 0.021±0.011
rs6074069 44,288.133 G/A 0.215 0.5557 −0.003±0.005 0.1256 −0.010±0.006 0.1892 0.009±0.007
rs2050113 44,293.878 A/C 0.075 0.0373 0.015±0.007 0.1416 0.013±0.009 0.0792 0.019±0.011
rs966567 44,300.632 G/C 0.242 0.7891 −0.001±0.004 0.4096 −0.005±0.006 0.5788 0.004±0.007
rs3904166 44,306.828 C/A 0.237 0.7528 −0.001±0.004 0.3851 −0.005±0.006 0.6170 0.003±0.007
rs3848729 44,308.103 G/T 0.360 0.0150 0.010±0.004 0.0108 0.013±0.005 0.6466 0.003±0.006
rs2425807 44,314.952 A/G 0.439 0.3675 0.004±0.004 0.0584 0.010±0.005 0.3480 −0.005±0.006
rs2425809 44,321.008 C/T 0.455 0.4152 0.003±0.004 0.0575 0.010±0.005 0.1974 −0.007±0.006
rs2425817 44,328.693 G/A 0.453 0.4154 0.003±0.004 0.0570 0.010±0.005 0.1728 −0.007±0.006
rs2425855 44,344.506 T/A 0.468 0.5482 0.002±0.004 0.1053 0.009±0.005 0.1133 −0.009±0.006
rs6032754 44,352.166 T/C 0.265 0.2331 −0.005±0.004 0.0256 −0.013±0.006 0.1036 0.011±0.006
rs6017767 44,365.336 C/G 0.479 0.4295 0.003±0.004 0.2188 0.006±0.005 0.8541 −0.001±0.006
rs6095091 46,441.248 C/T 0.262 0.0292 0.011±0.004 0.0152 0.015±0.005 0.7758 0.003±0.006
rs6066724 46,451.845 G/A 0.289 0.0038 0.013±0.004 0.0018 0.018±0.006 0.6074 0.004±0.006
rs2008645 46,458.897 G/A 0.423 0.0931 0.007±0.004 0.0091 0.014±0.005 0.3998 −0.003±0.006
rs4809688 46,461.222 A/G 0.438 0.2546 0.005±0.004 0.0350 0.011±0.005 0.2779 −0.005±0.006
Replicated region
3′ of PREX1
rs999151 46,488.676 C/T 0.291 0.0015 0.015±0.004 0.0022 0.019±0.006 0.6512 0.004±0.006
rs7263053 46,496.933 C/T 0.273 0.0109 0.011±0.004 0.0144 0.014±0.006 0.9664 0.002±0.007
rs1321006 46,499.668 G/A 0.355 0.0038 0.012±0.004 0.0089 0.014±0.005 0.8033 0.003±0.006
rs4809696 46,507.214 T/C 0.352 0.0038 0.012±0.004 0.0109 0.013±0.005 0.6947 0.003±0.006
rs926693 46,512.364 A/G 0.471 0.0045 0.011±0.004 0.0125 0.012±0.005 0.7415 0.003±0.006
rs926692 46,515.682 A/C 0.472 0.0053 0.011±0.004 0.0127 0.013±0.005 0.8798 0.002±0.006
rs12624650 46,526.719 G/A 0.201 0.1647 0.006±0.005 0.0406 0.012±0.006 0.3010 −0.007±0.007
rs6019212 46,527.953 G/T 0.461 0.0056 0.011±0.004 0.0089 0.013±0.005 0.9358 0.002±0.006
rs6019216 46,530.327 G/A 0.271 0.1533 0.005±0.004 0.1067 0.008±0.005 0.3320 −0.006±0.006
rs6122689 46,533.130 C/T 0.176 0.0682 0.010±0.005 0.2326 0.008±0.006 0.2654 0.010±0.008
rs12481537 46,572.852 A/G 0.474 0.0159 0.010±0.004 0.0562 0.010±0.005 0.6199 0.003±0.006
rs2904081 46,593.440 C/G 0.303 0.8359 0.001±0.004 0.8794 0.002±0.005 0.5358 −0.004±0.006
rs4810813 46,601.875 T/C 0.319 0.7201 0.000±0.004 0.6625 0.000±0.005 0.7271 −0.002±0.006
rs6019300 46,634.916 A/G 0.456 0.9065 0.000±0.004 0.9455 0.001±0.005 0.2973 −0.007±0.006
rs6090875 46,641.633 T/C 0.241 0.9511 0.000±0.005 0.8617 0.001±0.006 0.8113 −0.001±0.007
rs3924220 46,642.853 T/C 0.244 0.8670 0.001±0.005 0.7664 0.002±0.006 0.8770 0.000±0.007
rs4810837 46,662.565 T/G 0.418 0.7858 −0.001±0.004 0.2829 0.006±0.005 0.0621 −0.010±0.006
rs6012501 46,672.841 G/C 0.440 0.6323 −0.002±0.004 0.4876 0.004±0.005 0.0593 −0.010±0.005
PREX1 rs2664570 46,674.765 C/T 0.210 0.3460 −0.004±0.005 0.3561 −0.006±0.006 0.8109 −0.001±0.007
rs3935549 46,686.895 C/T 0.489 0.9600 −0.001±0.004 0.2332 −0.008±0.005 0.0214 0.013±0.005
rs2073072 46,703.010 C/G 0.205 0.9508 −0.001±0.005 0.7675 0.002±0.006 0.8574 0.000±0.007
rs2294910 46,709.789 A/G 0.205 0.8618 0.001±0.005 0.7979 0.002±0.006 0.9837 0.001±0.007
rs6095228 46,713.283 G/A 0.087 0.4407 −0.005±0.006 0.4604 0.008±0.009 0.0763 −0.014±0.008
rs6012506 46,719.044 A/G 0.477 0.9783 0.000±0.004 0.2386 0.007±0.005 0.0357 −0.012±0.006
rs6095239 46,730.946 G/A 0.332 0.8347 −0.001±0.004 0.6831 0.003±0.006 0.2004 −0.008±0.006
rs3746819 46,741.342 A/G 0.090 0.4284 −0.006±0.007 0.5773 0.006±0.009 0.0314 −0.021±0.009
rs4809718 46,744.395 T/A 0.211 0.9615 0.001±0.005 0.2891 0.008±0.006 0.0649 −0.013±0.007
rs736659 46,757.117 G/A 0.214 0.9392 0.001±0.005 0.3171 0.008±0.006 0.0654 −0.013±0.007
Bold: P-valuesb0.05.
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Table 6
Effect mediated by BMI on SNPs associated with T2DM 3′ of PREX1.
761 cases and 407
controls
Mediation analysis
SNP T2DM
Pa-value
BMI
Pa-value
Sobel
P-value
Goodman
P-value
Mediated
effect
rs1321006 0.025 0.004 0.010 0.010 0.39
rs4809696 0.025 0.004 0.010 0.010 0.40
rs926693 0.010 0.004 0.010 0.010 0.33
rs926692 0.013 0.005 0.010 0.010 0.30
rs6019212 0.016 0.006 0.010 0.010 0.38
rs6019216 0.044 0.153 0.160 0.160 0.19
rs12481537 0.016 0.016 0.020 0.020 0.30
Bold: mediation effects are valid based on Sobel and Goodman tests.
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and CDH22 results were from cases with diabetes and ESRD. There is no
biological information that supports a role for either NCOA5 or CDH22
with any form of nephropathy, although we cannot discount the effects
of these genes based on this information alone.
SNPs that were associated with T2DM in the DHS population
were those located 102–184 kb 3′ of PREX1. More speciﬁcally, this
area is part of a larger 800 kb ‘gene desert’ region ﬂanked by SULF2
(sulfatase 2) and PREX1 (45.9–46.7 Mb, UCSC Genome Browser,
March 2006 assembly). There are no annotated genes in the region
that showed evidence of association and only 1 short mRNA found in
testis [33]. In addition, none of the associated SNPs genotyped 3′ of
PREX1, with the exception of rs4809696, are located in any LINE or
SINE human repeats or long segmental duplications that may cause
spurious evidence of association. rs4809696 is located in a 205 bp L1
family member of the LINE superfamily (L1MDa) [33]. Not unlike
previous investigations, this is another example of non-genic regions
of DNA that are signiﬁcantly associated with T2DM [35,37,48].
In the combined T2DM-ESRD and DHS population analysis we
generally observed stronger evidence of associationwith T2DMwith the
SNPs 3′ of PREX1while no evidencewas observed inNCOA5 or CDH22. It
is possible that the lack of association in NCOA5 and CDH22 in the
combined population could be the result of heterogeneity between the
DHS and T2DM-ESRD populations. However, we have no evidence that
T2DM is expressed differently in the presence of ESRD. In fact, prior
investigations in our laboratory examining other candidate genes have
shown little to no differences in T2DM association results when
comparing populations with or without ESRD. Detailed haplotype
analyses in the region 3′ of PREX1 showed both common and rare ﬁve-
SNP haplotypes in this area were associated with altered risk for T2DM.
If one takes into consideration that multiple SNPs were genotyped,
correcting for multiple comparisons using a Bonferroni adjustment
would result in no association P-values reaching the designated
threshold (0.00053). However, due to the presence of LD among
associated SNPs and the a priori nature of this study based on linkage
results we believe that such a correction method is too stringent.
To better understand the relationship between the genotyped
SNPs, adiposity, and T2DM, we repeated the association test
accounting for BMI resulting in only two SNPs remaining marginally
associated with T2DM in the region and six others trending towards
signiﬁcance with Pa-values ranging from 0.055 to 0.092. Subsequent-
ly, we tested whether these SNPs were associated with BMI itself and
observed evidence of association comparable to that observed with
T2DM. The test for association between BMI and these SNPs stratiﬁed
by T2DM status identiﬁed 13 SNPs that were signiﬁcantly associated
with BMI solely in the case stratum suggesting that BMI may mediate
the effect of these SNPs on T2DM. A formal mediation analysis
revealed that approximately 30–40% of the effects six SNPs have on
T2DM risk are signiﬁcantly mediated by BMI. It is well known that
obesity is a signiﬁcant risk factor in the development of T2DM. In
addition, there is strong evidence to suggest that various measures ofobesity (i.e. BMI) and T2DM might be inﬂuenced by the same genetic
and environmental factors. Therefore, it is sensible to imagine a causal
pathway where the effect of these factors on T2DM is mediated by
obesity. These results suggest that SNPs near the PREX1 gene may
contribute to diabetes susceptibility, which is mediated through
effects of adiposity in European Americans.
These results, driven by extensive evidence in family studies, leads
to the question of whether these associated SNPs are the basis for the
prior evidence of linkage. The family sample in our study which lead
us to focus on this region of chromosome 20 [1] is quite modest by
current standards and has little power to address this issue. These
results do, however, suggest a reappraisal of linkage in other study
populations. This may be especially pertinent with the reemerging
interest in family studies.
In conclusion, we have evaluated three candidate genes (NCOA5,
CDH22, and PREX1) in the 20q12-13.13 T2DM-linked region on
chromosome 20. Although we could not replicate these ﬁndings for
NCOA5 and CDH22 in an independent population, recent reports and/
or preliminary functional studies in our laboratory suggest there may
be a role for these genes in T2DM risk. SNPs in a region 3′ of PREX1
were also associated with T2DM in two independent populations.
Takeuchi et al. recently described evidence of association with T2DM
near PREX1 [49]. Interestingly, the effect of these SNPs located 3′ of
PREX1 on T2DM risk are in some way mediated by measures of
adiposity. Further evaluation of these genes is necessary to under-
stand the biological impact these polymorphisms have on both T2DM
and adiposity, but this study demonstrates the importance of targeted
intensive analysis of genomic regions to locate T2DM genes.
4. Research design and methods
4.1. Subjects
Two independently recruited collections of T2DM patients and
control subjects have been evaluated in this study. The ﬁrst group
consisted of 300 unrelated EA T2DM patients with end-stage renal
disease (ESRD) and 310 randomly ascertained unrelated EA controls
without known diabetes or renal disease. Collectively, this group is
referred to here as the ‘T2DM-ESRD’ population. Their recruitment has
been previously described in detail [18–20]. Brieﬂy, both cases and
controls were recruited simultaneously. The T2DM-ESRD cases had a
mean age at diagnosis of T2DMof 46.5 years, amean duration of T2DM
greater than 15 years, a mean BMI of 28.5 kg/m2, and amean HbA1c of
8.6%. Controls had a mean age of 45.8 years and no BMI data available.
The second collection of T2DM-affected participants consisted of
470 probands from the Diabetes Heart Study (DHS) [21]. The DHS is a
single-center family-based study of atherosclerosis in T2DM-enriched
families. These participants (DHS cases) had a mean age of diagnosis
of T2DM of 51.6 years old, mean BMI of 33.0 kg/m2, a mean duration
of T2DM of 11.2 years, and a mean HbA1C of 7.5%. Unlike the T2DM-
ESRD cases, DHS participants were recruited with an exclusion of
diabetic nephropathy. As a control population for this group we
genotyped DNA from 442 unrelated healthy self-declared EA subjects,
who had a mean age of 57.3 years old and a mean BMI of 28.1 kg/m2.
Collectively, this case–control sample is referred to as the ‘DHS’
population. This study was approved by the Institutional Review
Board of Wake Forest University School of Medicine and was in
accordance with the principles of the Declaration of Helsinki.
4.2. SNP selection and genotyping
All SNPs were selected from the dbSNP database prior to phase II of
the HAPMAP project. SNPs were preferentially selected that were
validated, had minor allele frequencies N0.1 in the Caucasian
European sample (CEU) of the HAPMAP project, and were spaced
evenly over the regions of interest. In the NCOA5-CDH22 region 50
218 J.P. Lewis et al. / Genomics 96 (2010) 211–219SNPs were selected for genotyping. Thirty four of these SNPs were
genotyped in the HAPMAP project and corresponded to a mean
r2N0.70 over the entire 296 kb region compared to a mean r2b0.39 in
our prior investigation. Similarly, in the PREX1 region (~316 kb) 45
SNPswere selected for genotyping, 33 of whichwere genotyped in the
HAPMAP project and corresponding to a mean r2N0.60 compared to a
mean r2b0.28 in our prior investigation [17].
Genotyping was performed using the Sequenom MassArray
genotyping system (Sequenom Inc., San Diego, CA) [22]. Primer
sequences are available upon request. SNP genotyping success rates in
the combined populationwere N95.3% in cases and N94.4% in controls.
Concordance between blind duplicate samples included in the
genotyping was N98%.4.3. Statistical analyses
Each SNP was tested for departures from Hardy–Weinberg
equilibrium (HWE) expectations by calculating a chi-square goodness
of ﬁt test. Structures of the haplotype blocks were ascertained using
Haploview 3.2 [23] using the criteria outlined in Gabriel et al. [24].
Measures of linkage disequilibrium (LD) and association were
calculated using the program SNPGWA [25]. For each pair of SNPs the
LD statistics D′ and r2 were computed. To test for an association
between a SNP and T2DM the primary inference was based on the
additive genetic model (Cochran-Armitage trend) and secondarily the
overall 2-degree of freedom (genotypic) test. To test for departures
from additivity a lack of ﬁt test was calculated. All single-SNP
association analyses were adjusted for age and sex, which did not
signiﬁcantly change the results. The haplotype frequencies in cases
and controls were calculated using the expectation-maximization
algorithm and compared using omnibus and haplotype-speciﬁc tests
implemented in PLINK [26]. Tests of genotypic association as well as
association under a priori genetic models adjusting for the effect of
body mass index were calculated using SNPGWA. Quantitative trait
association analyses were performed using a module of SNPGWA
(QSNPGWA) [25]. BMI values were log-transformed to approximate
normal distribution prior to analysis.
As part of this study we have carried out a Mendelian random-
ization analysis to test for the mediator effect of BMI on the
association of the risk allele of a genetic locus with the outcome
measure T2DM. Speciﬁcally, we tested if the effect of the allele on
T2DM varies with the levels of BMI such that BMI may account for
some of the correlation observed between the risk allele and T2DM
[27–29]. This deﬁnition in itself is valid for both confounding and
mediation effects. Statistical mediation has proven to be a valuable
tool for understanding complex relationships between three or more
variables, but this approach by itself is not sufﬁcient to tease apart a
confounding effect from a mediation effect.
Conventional mediation analyses assumes that both the mediator
and outcome are continuous variables [30]. For example, three linear
models are ﬁtted: one for the direct effect of the independent variable
(X) on the outcome of interest (Y), another for testing the same effects
after adjusting for the mediator (Z), and ﬁnally, a model that tests for
association between the independent variable (X) and the mediator
(Z). The appropriate parameter estimates from each model are then
combined into a statistical test for mediation. This approach was
modiﬁed in our analysis since the outcome variable (T2DM) and
independent variable (locus allele) were binary in nature. In this case,
the estimated parameters needed to be standardized to account for
the difference in scale observed between logistic and linear regres-
sions. Here we have used the scalingmethods described inMackinnon
et al., 1993 and the SAS macro provided by Jasti et al., 2008 to test
whether obesity measured by BMI is mediator of the effect between
SNPs within PREX1 and T2DM [28,31]. Statistical signiﬁcance was
evaluated using large sample tests where the variance of themediation parameter estimate is computed using both Sobel's [30]
and Goodman's formulations [32].
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